Get 40% Off
These stocks are up over 10% post earnings. Did you spot the buying opportunity? Our AI did.Read how

Ackman urges Allergan talks with Valeant, no delay to special meeting

Published 07/16/2014, 10:21 AM
Updated 07/16/2014, 10:30 AM
Ackman urges Allergan talks with Valeant, no delay to special meeting

By Rod Nickel

(Reuters) - Activist investor Bill Ackman urged Botox maker Allergan Inc (N:AGN) to negotiate a possible takeover by Valeant Pharmaceuticals Inc (TO:VRX) and not delay a special shareholder meeting that could overturn most of Allergan's board.

Ackman's Pershing Square Capital Management hedge fund, Allergan's largest shareholder with a 9.7 percent stake, is attempting to gain support of shareholders owning 25 percent of Allergan to call a special meeting, during which it would seek to remove six directors.

Allergan can delay the meeting until as late as November.

"We, on behalf of Allergan's other shareholders, ask that you do not delay the inevitable any further," Ackman wrote in a letter to Allergan's board, released on Wednesday. "What legitimate board of directors attempts to silence or otherwise delay hearing what its own shareholders have to say?"

Ackman also called Allergan's criticism of Valeant a "scorched earth response" and said spreading false information to drive down Valeant's stock would be market manipulation.

Allergan, known for its Botox anti-wrinkle injections, said that Ackman's economic interests were aligned with Valeant's and he was trying to distract Allergan shareholders from the fact that Valeant's offer is too low.

"Pershing Square's letter to the Allergan Board is not based on facts, and is rooted purely in self-interest and innuendo," said an Allergan spokesperson.

Laval, Quebec-based Valeant, made an unsolicited cash and stock bid for California-based Allergan in April and has since raised its $51-billion offer.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Allergan shares edged up 0.1 percent at $164.51 in midday trading in New York, while Valeant stock added 1 percent to $120.60.

(Reporting by Rod Nickel in Winnipeg, Manitoba and Ransdell Pierson in New York; Editing by Bernadette Baum)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.